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Insulin-like growth factors (IGFs) are critical components of the stem cell niche, as they regulate proliferation and diﬀerentiation of
stem cells into diﬀerent lineages, including skeletal muscle. We have previously reported that insulin-like growth factor binding
protein-6 (IGFBP-6), which has high aﬃnity for IGF-2, alters the diﬀerentiation process of placental mesenchymal stem cells
(PMSCs) into skeletal muscle. In this study, we determined the roles of IGF-1 and IGF-2 and their interactions with IGFBP-6.
We showed that IGF-1 increased IGFBP-6 levels within 24 hours but decreased after 3 days, while IGF-2 maintained higher
levels of IGFBP-6 throughout myogenesis. IGF-1 increased IGFBP-6 in the early phase as a requirement for muscle
commitment. In contrast, IGF-2 enhanced muscle diﬀerentiation as shown by the expression of muscle diﬀerentiation markers
MyoD, MyoG, and MHC. IGF-1 and IGF-2 had diﬀerent eﬀects on muscle diﬀerentiation with IGF-1 promoting early
commitment to muscle and IGF-2 promoting complete muscle diﬀerentiation. We also showed that PMSCs acquired increasing
capacity to synthesize IGF-2 during muscle diﬀerentiation, and the capacity increased as the diﬀerentiation progressed
suggesting an autocrine and/or paracrine eﬀect. Additionally, we demonstrated that IGFBP-6 could enhance the muscle
diﬀerentiation process in the absence of IGF-2.
1. Introduction
Insulin-like growth factor (IGF) system regulates cell growth,
diﬀerentiation, migration, and cell survival through activa-
tion of several receptor-dependent signal transduction path-
ways [1]. The IGF family consists of two IGF ligands (IGF-1
and IGF-2), three cell surface receptors (IGF-1 and IGF-2
receptors and the insulin receptor), and six IGF binding
proteins (IGFBPs) [1]. IGF-1 and IGF-2 are circulating
peptides, which bind IGF-1R, a ligand-activated receptor
tyrosine kinase, for their biological actions [1, 2]. IGFBPs
act as carriers for IGFs in the circulation [3], protecting
them from degradation [2, 4] and regulating the biological
actions of IGFs by delivering them to speciﬁc tissues. The
IGF family plays an important role in fetal and placental
development by stimulating proliferation, diﬀerentiation,
and survival of various types of placental cells [5]. IGFs
are vital in cell growth, development, and cell-fate changes
through several mitogen activation cascades [6–9]. The
IGF family is also important in muscle development as
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IGFs maintain muscle cell viability, promote hypertrophy,
and stimulate diﬀerentiation in cultured myoblasts [9].
The importance of IGFs and the IGF-1R in skeletal muscle
development is demonstrated in the loss-of-function ani-
mal models. IGF-1R knockout mice die soon after birth
as functional respiratory muscle is deﬁcient and pups are
unable to breathe [10, 11]. Furthermore, IGF-1 and IGF-
2 are expressed by skeletal muscle cells during muscle
repair in response to muscle injury and exercise [12, 13].
IGFs are the only factors known to promote both muscle
cell proliferation and diﬀerentiation [13]. In response
to muscle injury, adult skeletal muscle regenerates by
expressing myogenic regulatory factors (MRFs) [13]. During
myogenesis, committed muscle cells diﬀerentiate into the
muscle lineage by expressing muscle commitment markers,
Pax3 and Pax7, which in turn upregulate MyoD and myo-
genin [14]. After commitment, myoblasts fuse together and
form multinucleated ﬁbers that express myosin heavy chain
(MHC) [14].
After muscle injury, IGF-1 enhances regeneration while
inhibiting IGF-1 activity with neutralizing antibodies, reduc-
ing the number of regenerating myoﬁbers in vivo [15]. IGF-2,
which upregulates its own gene expression during myogen-
esis in a positive feedback loop [12], is expressed abundantly
in the developing skeletal muscle and is the major growth
factor for muscle growth, diﬀerentiation, and regeneration
[12, 13]. When IGF-2 is inhibited, myogenesis does not
occur [16]. In fact, IGF-2 is required to allow the continued
recruitment of MyoD-associated proteins at the myogenin
promoter [17]. Moreover, in cultured myoblasts, IGFs stim-
ulate terminal diﬀerentiation through an autocrine pathway
that is dependent on IGF-2 secretion [18].
IGFBPs also play a role in fetal and placental develop-
ment as they are expressed during diﬀerent stages of
development in a time-speciﬁc and cell-speciﬁc manner.
Although loss-of-function studies targeting single IGFBP
genes have not yielded signiﬁcant phenotypic changes in
the fetus or placenta, it is thought that there are subtle
changes in development which are possibly due to biologic
compensation by other binding proteins or redundancy.
IGFBP-6, a member of the IGF binding protein family, is
expressed abundantly in developing muscle cells and is
required for myogenesis [13]. It is a unique peptide among
the IGFBPs due to its higher binding aﬃnity to IGF-2
versus IGF-1 (~70- to 100-fold) [19–22]. The most com-
monly reported function of IGFBP-6 is the modulation
of IGF-2 activity. IGFBP-6 binds IGF-2 in the circulation
and prevents it from binding to the cell surface receptors
and modulates IGF-2 bioavailability in vitro and in vivo
[23, 24]. IGFBP-6 can also bind and localize IGF-2 at
the cell surface, enhancing IGF-2 actions by delivering
IGF-2 to the IGF-1R [24]. However, the mechanisms con-
trolling the multiple actions of IGFBP-6 remain unclear.
Previous studies in our lab have shown that both extracellular
and intracellular IGFBP-6 are required for myogenesis. In
this study, we determined the diﬀerent biologic roles of
IGF-1 and IGF-2 and whether IGFBP-6’s impact on PMSC
diﬀerentiation into skeletal muscle is dependent or indepen-
dent of IGFs (particularly IGF-2).
2. Materials and Methods
2.1. Isolation of PMSCs. PMSC isolation and experiments
were conducted in accordance with the approval from
the Health Sciences Research Ethics Board of Western
University. Informed consent was obtained from healthy
women undergoing therapeutic termination of pregnancy,
and the PMSCs used in this study were isolated from 15
weeks preterm placental tissues. After surgery, chorionic villi
were dissected, washed, minced with surgical scissors and
forceps, and then subjected to enzymatic digestion with
collagenase IV (369 IU/mg), hyaluronidase (999 IU/mg)
(Sigma-Aldrich, Oakville, ON), and DNase I (2000 IU/mg)
(Hoﬀmann-La Roche, Mississauga, ON) for 10 minutes
at room temperature, followed by 0.05% trypsin (Gibco/
Invitrogen, Mississauga, ON) for 5 minutes at room temper-
ature. The sample was then washed for 10 minutes with 10%
FBS in DMEM/F12 medium, and the resulting single cell
suspension was separated by density centrifugation over a
Percoll (Sigma-Aldrich, Oakville, ON) discontinuous gradi-
ent using a modiﬁed protocol by Worton et al. [25, 26].
PMSCs isolated were validated for the expression of
stem cell markers (CD73, CD105, and CD-117/c-Kit) and
diﬀerentiation ability [26].
2.2. Muscle Diﬀerentiation and IGFs Treatment. Cells
were plated in muscle growth media (fetal bovine serum
0.05mL/mL, fetuin 50μg/mL, epidermal growth factor
10 ng/mL, basic ﬁbroblast growth factor 1 ng/mL, insulin
10μg/mL, and dexamethasone 0.4μg/mL) for 48 hours
before changing to the skeletal muscle diﬀerentiation
media, which is a proprietary serum-free medium containing
10μg/mL insulin (PromoCell, Heidelberg, Germany) [26],
with or without 100ng/mL of either IGF-1 or IGF-2 (Cell
Signaling Technology, Danvers, MA). IGFs were added every
3 days at the time of media change. Cells were grown in
six-well plates in a standard tissue culture incubator at
37°C in 5% CO2.
2.3. Downregulation of IGF-2 Expression by siRNA. To silence
the endogenous IGF-2 expression, siRNA against IGF-2
(Santa Cruz Biotechnology, Dallas, TX) was used. 8μL of
Lipofectamine (Invitrogen, Mississauga, ON) with 8μL of
either scrambled or IGF-2 siRNA was added to 100μL
of DMEM/F12 media (Invitrogen, Mississauga, ON) for
40 minutes at room temperature. siRNA was added to
the 70% conﬂuent cells and incubated for 5 hours at 37°C.
Muscle growth media (1.5mL) was added for 48 hours, then
changed to muscle diﬀerentiation media (2mL) (PromoCell,
Heidelberg, Germany).
2.4. IGFBP-6. Recombinant human IGFBP-6 (ProSpec, East
Brunswick, NJ) was added to the media (375 ng/mL) every
3 days at the time of media change. The IGFBP-6 concentra-
tion was determined by a dose-response curve using PMSCs
in muscle diﬀerentiation media [26].
2.5. Immunoblotting. Following PMSC culture, cell lysates
containing 20μg of protein were added to 6x SDS gel
loading buﬀer (1%β-mercaptoethanol, 1% SDS, 30% glycerol,
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0.0012% bromophenol blue, Tris-HCl 0.28M, pH6.8). Sam-
ples were boiled for 5 minutes at 95°C, then placed on ice for
3 minutes, and centrifuged at 3000 rpm for 20 seconds
before loading. Samples were resolved by molecular weight
using 10% SDS polyacrylamide gels transferred onto polyvi-
nylidene ﬂuoride (PVDF) membranes (Bio-Rad, Hercules,
CA) using a Trans-Blot Turbo (Bio-Rad, Hercules, CA) with
an optimized protocol depending on protein size. Mem-
branes were blocked with 5% nonfat dry milk, gently shaking
for 1 hour at room temperature in Tris-HCl buﬀered saline
pH8.0 with 0.1% Tween-20 (TBS-T). Blots were then
washed with TBS-T (3 times for 10 minutes) followed by
incubation at 4°C overnight with speciﬁc primary antibodies
in 5% BSA or 5% nonfat dry milk in TBS-T following the
manufacturer’s protocol. Then, membranes were washed
and incubated for 1 hour at room temperature with the cor-
responding secondary HRP-conjugated antibody. Resolved
protein bands were detected using chemiluminescence, and
images were taken using the VersaDoc Imager (Bio-Rad,
Hercules, CA) [26].
2.6. Immunocytochemistry. PMSCs were grown on glass
coverslips, stained with primary antibodies (1 : 100), and
incubated at 4°C overnight. Primary antibodies were washed
using 0.1% Tween-20 in PBS (3 times for 5 minutes); cells
were then incubated in the dark with the corresponding
secondary Alexa Flour conjugated antibody (1 : 200). The
secondary antibody was washed using 0.1% Tween-20 in
PBS (3 times for 5 minutes), and the nuclear stain was added
for 7 minutes and then rinsed. The cover slips were mounted
and images were taken using a confocal microscope (Zeiss,
Germany) [26].
2.7. Antibodies. To detect stem cell-associated potency
markers, antibodies for OCT4 (N-19: sc-8628) (Santa
Cruz Biotechnology, Dallas, TX), SOX2 (2683-1) (Epi-
tomics, Burlington, ON), and Nanog (3369-1) (Epitomics,
Burlington, ON, Canada) were used. To detect markers of
muscle diﬀerentiation, Pax3/7 (E-10: sc-365613), MyoD
(M-318: sc-760), myogenin (F5D: sc-12732), and myosin
heavy chain (H-300: sc-20641) (Santa Cruz Biotechnology,
Dallas, TX) were used. To detect IGFBP-6, antibody H-70:
sc-13094 (Santa Cruz Biotechnology, Dallas, TX) was used.
To detect IGF-2, antibody H-103: sc-5622 (Santa Cruz
Biotechnology, Dallas, TX) was used. For loading control,
pan-Actin Ab-5 (Thermo Fisher Scientiﬁc, Fremont, CA)
was used. The secondary antibodies used for immunoblot-
ting were HRP-conjugated goat anti-rabbit (#170-6515) or
anti-mouse (#170-6516) (Bio-Rad, Hercules, CA) or don-
key anti-goat antibody (Santa Cruz Biotechnology, Dallas,
TX). The secondary antibodies used for immunocytochem-
istry were green-Alexa 488 or red-Alexa 568 (Invitrogen,
Mississauga, ON).
2.8. Quantiﬁcation of IGFBP-6 and IGF-2 by Enzyme-Linked
Immunosorbent Assay (ELISA). Human IGFBP-6 (RayBio-
tech®, Burlington, ON) and IGF-2 (ALPCO, Salem, NH)
ELISA kits were used to measure the amount of IGFBP-6
and IGF-2 secreted into PMSC conditioned media. Standards
and samples were loaded into the wells and the immobilized
antibody bound IGFBP-6 or IGF-2 present in the sample.
The wells were washed and biotinylated anti-human anti-
body was added. After washing, HRP-conjugated streptavi-
din was added; then, a TMB substrate solution was used
to develop a blue color in proportion to the amount of
IGFBP-6 or IGF-2 bound. The Stop Solution changes color
from blue to yellow, and the intensity was measured at
450 nm using Multiskan Ascent plate reader and analysis
software [26].
2.9. Aldehyde Dehydrogenase (ALDH) Activity. ALDH activ-
ity, a conserved progenitor cell function, was assessed by ﬂow
cytometry. Using the Aldeﬂuor™ assay (Stem Cell Technolo-
gies, Vancouver, BC), as per the manufacturer’s instructions.
Brieﬂy, 5μL of activated Aldeﬂuor reagent was added to 1mL
of cell suspension and incubated for 45 minutes at 37°C. Cells
were washed and resuspended in 500μL of ice-cold Aldeﬂuor
assay buﬀer and ALDH activity was measured using ﬂow
cytometry. As a negative control, Aldeﬂuor DEAB reagent
was used [26]. Samples were run in triplicate.
2.10. Statistical Analysis. All experiments were performed in
triplicate using the cells from 3 PMSC samples (N = 3).
GraphPad Prism Software 5.0 was used to generate all graphs
and analyses. A two-way ANOVA followed by a Bonferroni’s
multiple comparison test or a one-way ANOVA followed by
a Student’s t-test was used to calculate signiﬁcant diﬀerences
when P < 0 05. Graphic representation values are presented
as mean± SEM (shown as variance bars).
3. Results
3.1. IGF-1 Aﬀects PMSC Multipotency and Diﬀerentiation
into Skeletal Muscle. To test the eﬀects of extracellular
IGF-1 on PMSC multipotency and diﬀerentiation into mus-
cle cells, IGF-1 was supplemented to muscle diﬀerentiation
media (100 ng/mL) every third day for up to 14 days.
OCT4 levels were not changed by IGF-1 supplementation
(Figure 1(a)), while both SOX2 (Figure 1(b)) and Nanog
(Figure 1(c)) levels were reduced at early time points com-
pared to unsupplemented muscle diﬀerentiation condi-
tions. In contrast, IGF-1 supplementation increased Pax3/
7 levels at 7 and 14 days suggesting PMSC commitment
to the muscle lineage (Figure 1(d)). Finally, IGF-1 treat-
ment decreased the levels of muscle-speciﬁc diﬀerentiation
marker, MyoD, at day 14 (Figure 1(e)), but did not
change MyoG and MHC levels (Figures 1(f) and 1(g)),
compared to PMSCs cultured under unsupplemented muscle
diﬀerentiation conditions.
Immunocytochemistry analyses at day 14 revealed that
PMSCs treated with IGF-1 showed qualitatively increased
Pax3/7, decreased MyoD, and no change in OCT4 and
MHC immunoreactivity (Figure 2), which was in agreement
with the analyses by Western blots. Moreover, IGF-1 treat-
ment signiﬁcantly increased the total number of cells com-
pared to unsupplemented controls (Supplementary Figure 1).
We also tested PMSCs for ALDH activity to determine
the frequency of cells that maintained high ALDH activity,
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Figure 1: Continued.
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a conserved phenotype of early progenitor cells in multiple
lineages [27–29]. Under muscle diﬀerentiation conditions,
IGF-1 treatment increased the frequency of cells with high
ALDH activity at all time points compared to PMSCs under
muscle diﬀerentiation alone (Figure 3 and Supplementary
Figures 2A to 2D) suggesting that extracellular IGF-1 treat-
ment prolonged progenitor cell phenotype in PMSCs cul-
tured under muscle diﬀerentiation conditions.
3.2. IGF-2 Aﬀects PMSC Multipotency and Diﬀerentiation
into Skeletal Muscle. The impact of IGF-2 in PMSC mul-
tipotency and diﬀerentiation into skeletal muscle was
investigated by adding IGF-2 (100ng/mL) to the muscle
diﬀerentiation media. Using Western blots, we demon-
strated that IGF-2 supplementation increased the protein
levels of pluripotency-associated marker OCT4 at days
3, 7, and 14 compared to PMSCs cultured in muscle dif-
ferentiation media alone (Figure 1(a)), whereas other
pluripotency-associated markers SOX2 (Figure 1(b)) and
Nanog (Figure 1(c)) were decreased. In contrast, IGF-2
supplementation increased the protein levels of the muscle
lineage commitment marker Pax3/7 and the levels of muscle
diﬀerentiation markers MyoD, MyoG, and MHC compared
to untreated controls (Figures 1(d) to 1(g)).
Using immunocytochemistry, PMSCs cultured under
muscle diﬀerentiation conditions supplemented with IGF-2
showed, qualitatively, no change in OCT4, Pax3/7, and
MyoD immunoreactivity (Figure 2). In contrast, expres-
sion of muscle diﬀerentiation marker MHC was increased
(Figure 2) at 14 days after IGF-2 treatment compared to
untreated controls, with fewer cells per ﬁeld (Supplementary
Figure 1) suggesting that IGF-2 enhanced the terminal
muscle diﬀerentiation process.
Moreover, IGF-2 supplementation of PMSCs under
muscle diﬀerentiation conditions decreased the frequency
of cells with high ALDH activity compared to PMSCs under
untreated muscle diﬀerentiation condition at all time points
(Figure 3 and Supplementary Figures 2A to 2D), suggesting
that IGF-2 promoted the diﬀerentiation of PMSCs into
skeletal muscle.
3.3. Extracellular IGFs Altered IGFBP-6 Levels. Using
Western blots, we showed increased cellular IGFBP-6 levels
with IGF-1 treatment at early time points, which coincided
with delayed muscle commitment as indicated by higher
levels of Pax3/7 levels (Figure 1(d)). In contrast, IGF-2 did
not increase IGFBP-6 levels until day 14 compared to PMSCs
under muscle diﬀerentiation only (Figure 4(a)). When com-
pared to PMSCs treated with IGF-1, IGF-2 treatment
increased IGFBP-6 levels at 7 and 14 days (Figure 4(a)) sug-
gesting that IGF-2 treatment stimulated IGFBP-6 synthesis
after PMSC commitment to the muscle lineage, whereas
IGF-1 eﬀect on IGFBP-6 synthesis occurred before PMSC
commitment to muscle.
To investigate the eﬀects of IGF-1 and IGF-2 on
IGFBP-6 secretion into conditioned media under muscle
diﬀerentiation conditions, IGFBP-6 in the PMSC media
was measured using ELISA. With IGF-1 treatment, IGFBP-
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Figure 1: IGF-1 and IGF-2 supplementation diﬀerently aﬀected levels of pluripotency-associated and muscle diﬀerentiation markers in
PMSC. (a) IGF-1 treatment had no eﬀect on OCT4 levels, while IGF-2 treatment increased OCT4 levels at 3, 7, and 14 days compared to
muscle diﬀerentiation alone. (b) SOX2 and (c) Nanog levels were decreased after IGF-1 treatment at early time points only, whereas IGF-2
treatment decreased SOX2 levels until day 7 and at all time points for Nanog. (d) Pax3/7 levels were increased at 7 and 14 days and did
not decrease after IGF-1 treatment, while IGF-2 treatment increased Pax3/7 levels at all time points but decreasing with time. (e) MyoD,
(f) MyoG, and (g) MHC protein levels did not change with IGF-1 supplementation, except for a decrease in MyoD levels at day 14. In
contrast, IGF-2 treatment increased muscle diﬀerentiation marker levels at all time points. Protein levels were quantiﬁed by densitometry
and normalized to β-actin. Data is presented as the mean± SEM of 3 independent experiments. Two-way ANOVA with Bonferroni’s
multiple comparison test was performed to determine ∗P < 0 05, ∗∗P < 0 01, and ∗∗∗P < 0 001 comparing control to muscle diﬀerentiation
conditions, or ###P < 0 001 comparing the same treatment over time.
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Figure 2: PMSCs treated with IGF-2 showed qualitatively increased immunoﬂuorescence for MHC at 14 days. Compared to PMSCs cultured
under muscle diﬀerentiation alone, PMSCs treated with IGF-1 or IGF-2 showed similar OCT4 immunoreactivity (red-Alexa, λ= 568 nm).
However, IGF-1 supplementation increased Pax3/7 IR (green-Alexa, λ= 488 nm), decreased MyoD IR, with no change in MHC IR
(red-Alexa, λ= 568 nm). In contrast, IGF-2 treatment did not alter Pax3/7 IR (green-Alexa, λ= 488 nm) or MyoD IR, but increased MHC
IR (red-Alexa, λ= 568 nm). Nuclei, stained with Hoechst dye (blue, λ= 340 nm). Immunocytochemistry was performed in triplicate with
each antibody.
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6 concentration was increased at early time points (days 1
and 3) and decreased at later time points (days 7 and 14)
compared to control PMSCs under muscle diﬀerentiation
conditions (Figure 4(b)). In contrast, IGF-2 treatment
increased IGFBP-6 secretion throughout diﬀerentiation
until day 14 (Figure 4(b)). Therefore, both IGFs increased
IGFBP-6 synthesis by PMSCs under muscle diﬀerentiation
conditions with the eﬀect of IGF-1 short lived and IGF-2
for a long duration.
3.4. Extracellular IGFBP-6 Maintains Muscle Diﬀerentiation
of PMSCs in the Absence of IGF-2. Previous studies in the
Han Laboratory showed that during PMSC diﬀerentiation
into skeletal muscle, IGF-2 secretion was signiﬁcantly
increased as compared to control (10% FBS), conﬁrming that
developing muscle cells express IGF-2 which is actively
secreted [26]. To evaluate the role of endogenous IGF-2 on
PMSC diﬀerentiation into skeletal muscle, IGF-2 mRNA
was silenced using siRNA treatment every 3 days for up to
14 days. PMSCs with IGF-2 knockdown showed less compact
muscle morphology compared to control (scrambled siRNA)
at day 14 (Figures 5(a) and 5(b)). The addition of IGFBP-6
together with IGF-2 siRNA permitted PMSCs compact
muscle morphology at 14 days (Figures 5(b) and 5(c)). As
expected, IGF-2 levels were decreased by IGF-2 knockdown
compared to scrambled siRNA control. However, IGF-2
levels were equivalent to control levels at day 14 although
IGF-2 siRNA was administered every 3 days (Figure 5(d))
indicating that siRNA-treatment was transient. Furthermore,
IGF-2 levels remained signiﬁcantly low at all of the time
points by the addition of IGFBP-6 with IGF-2 knockdown
and did not return to control levels (Figure 5(d)), suggesting
an interaction between IGF-2 and IGFBP-6.
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Figure 4: IGFBP-6 expression is altered by IGF-1 and IGF-2
treatment in PMSCs cultured under skeletal muscle diﬀerentiation
conditions. (a) IGFBP-6 levels were increased by IGF-1 treatment
at days 1 and 3 compared to PMSCs under muscle diﬀerentiation
alone; however, they were reduced at days 7 and 14. IGF-2
treatment did not change IGFBP-6 levels until day 14 when they
were increased compared to controls. IGFBP-6 levels were
quantiﬁed by densitometry and normalized to β-actin. (b) IGFBP-
6 secretion into conditioned media was increased with both IGF-1
(days 1 and 3) and IGF-2 (days 1 to 7) compared to controls.
However, secreted IGFBP-6 levels were signiﬁcantly decreased at 7
and 14 days with IGF-1 treatment, and remained increased with
IGF-2 treatment. Data is presented as the mean± SEM of 3
independent experiments. Two-way ANOVA with Bonferroni’s
multiple comparison test was performed to determine ∗P < 0 05,
∗∗P < 0 01, and ∗∗∗P < 0 001 compared to control (PMSCs under
muscle diﬀerentiation), or #P < 0 05 and ###P < 0 001 comparing
between IGF-1 and IGF-2 treatments.
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Figure 5: IGF-2 knockdown with siRNA inhibited PMSC diﬀerentiation into skeletal muscle and adding extracellular IGFBP-6 with the
treatment helped rescue muscle compaction. (a) Compared to PMSCs under muscle lineage diﬀerentiation conditions with siRNA
scrambled control, (b) PMSCs under muscle diﬀerentiation conditions treated with IGF-2 siRNA showed less skeletal muscle compaction
at 14 days (10x). (c) Extracellular IGFBP-6 supplementation with IGF-2 knockdown enhanced the PMSC muscle compaction at 14 days
compared to IGF-2 siRNA. The white arrows indicate muscle compaction. (d) IGF-2 levels by PMSCs treated with IGF-2 siRNA under
diﬀerentiation conditions were reduced and returned to control levels by day 14, while adding IGFBP-6 with IGF-2 knockdown
maintained lower IGF-2 levels. (e) IGFBP-6 protein levels increased until day 3 with IGF-2 knockdown compared to siRNA scrambled
control. IGFBP-6 addition with IGF-2 knockdown increased IGFBP-6 protein levels at each time point. Protein levels were quantiﬁed by
densitometry and normalized to β-actin. Data is presented as the mean± SEM of 3 independent experiments. Two-way ANOVA with
Bonferroni’s multiple comparison test was performed to determine ∗P < 0 05, ∗∗P < 0 01, and ∗∗∗P < 0 001 compared to scrambled siRNA
control, or #P < 0 05 and ###P < 0 001 compared to IGF-2 siRNA.
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After IGF-2 knockdown, IGFBP-6 levels were increased
until day 3 compared to scrambled siRNA control
(Figure 5(e)), suggesting greater availability of IGFBP-6
demonstrated by an increase in secreted IGFBP-6 (Supple-
mentary Figure 3). As expected, IGFBP-6 protein levels
were signiﬁcantly increased at each time point during
IGF-2 siRNA treatment alongside extracellular IGFBP-6
supplementation compared to controls (Figure 5(e)).
Concurrent with IGF-2 knockdown, we observed a
decrease in pluripotency-associated marker OCT4 levels
until day 3 with an increase at day 14 compared to scrambled
siRNA control (Figure 6(a)). In contrast, SOX2 levels did not
change (Figure 6(b)). Furthermore, the addition of IGFBP-6
with IGF-2 knockdown reduced both OCT4 (Figure 6(a))
and SOX2 (Figure 6(b)) levels. The protein levels of muscle
lineage diﬀerentiation markers MyoD (Figure 6(c)) and
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Figure 6: IGF-2 knockdown decreased muscle diﬀerentiation markers, while adding IGFBP-6 partially increased the markers. (a) OCT4
levels were reduced with IGF-2 knockdown until day 3 and increased at day 14. Adding IGFBP-6 alongside IGF-2 siRNA reduced OCT4
protein levels at all-time points compared to siRNA scrambled control. In contrast, (b) SOX2 levels did not change with IGF-2
knockdown. But when IGFBP-6 was added with IGF-2 silencing, the levels were reduced from 1 to 3 days compared to control and IGF-2
knockdown. Protein levels of muscle diﬀerentiation markers: (c) MyoD and (d) MHC decreased with IGF-2 siRNA and IGFBP-6
supplementation increased the levels. Protein levels were quantiﬁed by densitometry and normalized to β-actin. Data is presented as the
mean± SEM of 3 independent experiments. Two-way ANOVA with Bonferroni’s multiple comparison test was performed to determine
∗P < 0 05, ∗∗P < 0 01, and ∗∗∗P < 0 001 compared to scrambled siRNA control, or #P < 0 05 and ###P < 0 001 compared to IGF-2 siRNA.
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MHC (Figure 6(d)) were decreased signiﬁcantly after IGF-2
knockdown indicating a critical role for IGF-2 in PMSC
diﬀerentiation into skeletal muscle. In contrast, IGFBP-6
supplementation alongside IGF-2 knockdown signiﬁcantly
increased MyoD and MHC levels at 7 and 14 days compared
to siRNA scrambled control or IGF-2 knockdown alone
(Figures 6(c) and 6(d)).
Knockdown of IGF-2 expression in PMSCs signiﬁcantly
decreased the abundance of cells with high ALDH activity
compared to control (scrambled siRNA) at day 1 (Figure 7
and Supplementary Figure 4). In contrast, the addition of
IGFBP-6 together with IGF-2 knockdown further decreased
the abundance of cells with high ALDH activity at all time
points compared to siRNA scrambled control or IGF-2
siRNA treatment (Figure 7 and Supplementary Figure 4).
Collectively, these data suggest that IGFBP-6 reduced pro-
genitor cell phenotype under muscle diﬀerentiation condi-
tions and maintained the diﬀerentiation of PMSCs towards
skeletal muscle in the absence of IGF-2.
4. Discussion
It is believed that if stem cells are to be used successfully in
cell-based therapies for speciﬁc diseases, they must be
initiated towards a progenitor cell of a desired lineage (e.g.,
skeletal muscle for therapy of muscular dystrophy) [30]. In
addition, adequate cell numbers will be needed for eﬀective
therapy. Human placenta, which is usually discarded fol-
lowing birth, is a potential source of adult mesenchymal
stem cells with functional capacity similar to bone marrow
[31–34]. PMSCs also demonstrate low tumorigenicity with
higher immunotolerance after transplantation, making them
an ideal cell type for tissue regeneration therapies [35, 36].
The IGF system is important for muscle development,
growth, regeneration, and diﬀerentiation [10, 11, 13, 37, 38].
IGF-2 plays an important role during C2C12 diﬀerentiation
and is considered the main myogenic factor in myoblast
cells [39]. In C3H 10T1/2 ﬁbroblasts converted to myo-
blasts by transfection of MyoD transgene, there was an
increase in the mRNA expression and protein levels of
IGF-2 during the diﬀerentiation stage [16]. In this study,
we showed that IGF-2 is synthesized and secreted into the
extracellular space by PMSCs during muscle diﬀerentiation
and the highest levels are expressed by fully diﬀerentiated
muscle cells. Taken together, these ﬁndings show the
important role of the IGFs, particularly IGF-2, in muscle
diﬀerentiation as autocrine/paracrine factors.
IGF-binding proteins act as carriers for IGF-1 and IGF-2
in the circulation, facilitating ligand delivery to speciﬁc tis-
sues and controlling access to the IGF receptors [2, 3, 40].
Also, IGFBPs are expressed by many cell types, including
skeletal muscle, and have been demonstrated to have func-
tions that are dependent or independent of IGF binding [4].
IGFBPs are expressed by developing muscle cells and are
important in myogenesis [40, 41]. In osteoblasts, IGFBP-6
has been shown to modulate cell growth by reducing the bio-
availability of IGF-2 in the bone microenvironment [42].
When L6E9 cells (a myoblast cell line used to study late
myogenesis) are stimulated with IGF-1, these cells initiate a
proliferative response. During this time of rapid cell division,
the myogenic regulatory factors are inhibited. Approximately
30 hours later, there is a stimulation of myogenin expression
[43]. In mouse C2C12 cells and C2 satellite cell line, there
are greater levels of IGF-2 mRNA than IGF-1, 2000-fold
to 20-fold, respectively [12, 19, 44]. Our study is one of
the ﬁrst to show the eﬀects of IGF-1 and IGF-2, in com-
bination with IGFBP-6, on human PMSC diﬀerentiation
into skeletal muscle in vitro.
The aim of this study was to characterize the eﬀects of
IGFs on the diﬀerentiation of PMSCs into skeletal muscle
and to delineate their interactions with IGFBP-6 in the
diﬀerentiation process. We showed previously that IGF-2
secretion into the condition media was increased during
and at the completion of muscle diﬀerentiation indicating
that the synthesis of IGF-2 increased as the cells became
more diﬀerentiated [26]. Moreover, increased IGFBP-6 in
the PMSC microenvironment is expected to reduce the
bioavailability of IGF-2 due to its high aﬃnity for the peptide,
conﬁrmed by IGF-2 ELISA [26].
In this study, we showed that IGF-1 can promote an early
increase in IGFBP-6 expression before PMSCs commit to
the muscle lineage, a requirement that delayed muscle
lineage commitment. This was conﬁrmed by the increased
levels of muscle commitment marker (Pax3/7) and decreased
muscle diﬀerentiation marker (MyoD) after IGF-1 treatment.
On the other hand, IGF-2 treatment increased both
IGBP-6 and OCT4 levels. These results are in agreement
with our previous studies [26], showing IGFBP-6 positive
eﬀects on OCT4 levels. Also, the muscle diﬀerentiation
markers (MyoD, MyoG, and MHC) were increased at
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Figure 7: IGF-2 knockdown and extracellular IGFBP-6 addition
in PMSCs under muscle diﬀerentiation conditions decreased the
frequency of cells with high ALDH activity. Compared to PMSCs
under muscle diﬀerentiation conditions (siRNA scrambled control),
cells treated with IGF-2 siRNA showed decreased frequency of cells
with high ALDH activity at day 1, while adding extracellular IGFP-
6 with IGF-2 siRNA showed decreased frequency of cells with
high ALDH activity at each time point. Data is presented as the
mean± SEM of 3 independent experiments. Two-way ANOVA
with Bonferroni’s multiple comparison test was performed to
determine ∗∗P < 0 01, and ∗∗∗P < 0 001 compared to scrambled
siRNA control, or ###P < 0 001 compared to IGF-2 siRNA.
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later time points with IGF-2 treatment, conﬁrming that IGF-
2 enhanced PMSC muscle diﬀerentiation, unlike IGF-1
(Figure 8). Increased OCT4 levels occurred alongside a
decrease in SOX2 and Nanog levels which is expected in a
mesodermal diﬀerentiation [45]; OCT4 is needed for diﬀer-
entiation as it supports downregulating pluripotency, and
when deﬁcient, cells are not able to diﬀerentiate [46].
IGF-1 and IGF-2 stimulate both proliferation and termi-
nal diﬀerentiation of many tissues in developing embryos
and adults. IGFBP-6 has a signiﬁcantly higher aﬃnity (~70–
100-fold) for IGF-2 than IGF-1 [19–22]. Previous studies in
C2C12 cells show that as muscle diﬀerentiation progressed,
IGF-2 stimulated its own expression and inhibited IGF-1
expression in a time- and dose-dependent manner [12]. In
our study, there was a decrease in the amount of secreted
IGF-2 to the media after IGF-1 treatment in PMSCs under
muscle diﬀerentiation conditions, indicating that an intri-
cate balance between IGF-1 and IGF-2 expression exists in
the niche during myogenesis from PMSCs (Supplementary
Figure 5). Further investigation will be conducted to delin-
eate these eﬀects.
Studies in various cell lines have shown mostly inhibitory
action of IGFBP-6 mainly via IGF-2-dependent mechanism.
In L6A1 myoblasts, recombinant human IGFBP-6 inhibited
muscle diﬀerentiation stimulated by IGF-2 in a dose-
dependent manner but had no eﬀect on IGF-1 induced
diﬀerentiation [47]. Moreover, IGFBP-6 expression has been
previously associated with nonproliferative states and inhi-
bition of IGF-2 dependent tumor cell growth in rhabdo-
myosarcoma, neuroblastoma, and colon cancer [48]. More
speciﬁcally, neuroblastoma cells undergo a decrease in both
cell proliferation and tumorigenic potency as a result of
exogenous IGFBP-6 expression as IGFBP-6 sequesters
IGF-2 preventing a mitogenic response in tumor cells
[49, 50]. Previous reports on the eﬀects of IGFs on muscle
diﬀerentiation used mouse cell lines [8, 12, 19, 39, 41, 44],
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Figure 8: Model of IGFs and IGFBP-6 functions during PMSCs myogenesis. During myogenesis, PMSCs lose pluripotency-associated
markers (OCT4, SOX2, and Nanog) and gain muscle commitment marker (Pax3/7) that decreased as muscle diﬀerentiation markers
increase (MyoG, MyoD, and MHC). Committed and diﬀerentiated muscle cells expressed IGF-1, IGF-2, and IGFBP-6. Extracellular IGF-1
increased IGFBP-6 protein levels before PMSC muscle commitment, resulting in a delayed PMSC muscle commitment and diﬀerentiation.
However, IGF-2 extracellular increase resulted in an increase in IGFBP-6 after commitment to the muscle lineage, resulting in full muscle
lineage diﬀerentiation. Increased IGF-2 and IGFBP-6 levels also had a positive eﬀect on OCT4 levels, but SOX2 and Nanog levels
were decreased.
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Figure 9: PMSC diﬀerentiation into skeletal muscle using the insulin-like growth factor system. PMSCs isolated from the chorionic villus of
preterm human placenta expressed high levels of pluripotency-associated markers under normal growth conditions (10% FBS). As these cells
diﬀerentiated into skeletal muscle, the levels of these markers decreased, and the cells committed to the muscle lineage, indicated by Pax3/7
expression. Once committed to diﬀerentiation, PMSCs subsequently decreased Pax3/7 expression and increased muscle diﬀerentiation
markers (MyoG, MyoD, and MHC) as myoblasts aligned and fuse to form multinucleated myoﬁbers. IGF-1 and IGF-2 binds to the
IGF-1R and activates its intrinsic tyrosine kinase activity resulting in signaling that accelerated muscle diﬀerentiation via downstream
signals including PI3K-AKT-mTOR and the RAF-MEK-ERK (MAPK) pathway. Due to IGFBP-6 intracellular and extracellular locations,
IGFBP-6 demonstrated both IGF-dependent and IGF-independent eﬀects on PMSC muscle diﬀerentiation. Extracellular IGFBP-6 binds
IGFs and enhances the muscle diﬀerentiation process through the IGF-1R, while intracellular IGFBP-6 directly impacted PMSC muscle
diﬀerentiation through an unknown mechanism.
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thus our study is one of the ﬁrst to show the eﬀects of
IGF-dependent functions of IGFBP-6 on human MSC
diﬀerentiation into skeletal muscle in vitro.
In this study, we focused on the role of IGFBP-6 and
IGF-2 in PMSCs under muscle diﬀerentiation conditions.
We showed that IGFBP-6 was required for PMSC diﬀerenti-
ation into skeletal muscle and modulated both multipotency
and muscle markers levels, as well as IGF-2 secretion.
When IGF-2 was knocked down using siRNA, myogenesis
was inhibited, and adding IGFBP-6 helped recover the
muscle diﬀerentiation process, supported by muscle mor-
phology and diﬀerentiation markers. Previous studies
[48–50] are in agreement with our ﬁndings, as IGF-2 levels
are signiﬁcantly reduced with the increase in extracellular
IGFBP-6.
Placenta development is dependent on the IGF system,
including IGF-1 and IGF-2 [51]. The importance of IGFs in
the human placenta is well deﬁned in mediating growth
and diﬀerentiation of the diﬀerent cells of the chorionic villi
[5, 52]. In the human placenta, IGF-2 mRNA is expressed
in the villous mesenchymal core, where PMSCs reside [51].
IGF-2 also plays a role in the placenta at the early gestation,
whereas IGF-1 is associated in later gestation [53]. Results
from this study showed that IGF-1 and IGF-2 had diﬀerent
eﬀects on PMSC diﬀerentiation into skeletal muscle in a
time-dependent manner. The role of IGF-1 and IGF-2 in
PMSC diﬀerentiation into skeletal muscle is not clearly
deﬁned and this study is the ﬁrst to show the diﬀerent eﬀects
between IGF-1 and IGF-2.
In conclusion, PMSC diﬀerentiation into skeletal mus-
cle is regulated by IGFs. IGF-1 delays PMSC commitment
towards the muscle lineage while IGF-2 enhanced myogen-
esis. IGFBP-6 is also required in this diﬀerentiation pro-
cess, and extracellular addition of IGFBP-6 alongside
IGF-2 inhibition suﬃciently rescued PMSC muscle diﬀer-
entiation. Since IGFBP-6 has both intracellular as well as
extracellular eﬀects, we showed that the eﬀects on muscle
diﬀerentiation are both IGF-dependent and IGF-independent
(particularly IGF-2) (Figure 9). Further investigation of
the balance between IGFs and IGFBP-6 in PMSCmyogenesis
and delineating the receptors and signaling mechanisms
governing muscle lineage development and regeneration
will improve the success of cellular therapies in muscu-
lar dystrophies.
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Supplementary Materials
Supplementary Figure 1: PMSCs under muscle diﬀerentia-
tion conditions treated with IGF-1 showed higher cell count,
while IGF-2-treated PMSCs were lower compared to PMSCs
in muscle diﬀerentiation alone. Data is presented as the
mean± SEM of 15 diﬀerent ﬁelds from 3 independent exper-
iments. One-way ANOVA followed by Student’s t-test was
performed to determine ∗∗∗P < 0 001 comparing to muscle
diﬀerentiation. Supplementary Figure 2: Representative ﬂow
cytometry dot plots from 3 independent experiments show-
ing the frequency of PMSC with high ALDH activity when
cultured under muscle diﬀerentiation conditions with or
without either IGF-1 or IGF-2 at (A) day 1, (B) day 3, (C)
day 7, and (D) day 14. DEAB-treated controls were used to
establish the ALDH gate. Supplementary Figure 3: IGFBP-6
levels secreted to the media increased with IGF-2 knockdown
compared to muscle diﬀerentiation using ELISA. Data is pre-
sented as the mean± SEM of 3 independent experiments.
Two-way ANOVA with Bonferroni’s multiple comparison
test; ∗∗∗P < 0 001. Supplementary Figure 4: Representative
ﬂow cytometry dot plots from 3 independent experiments
showing the frequency of PMSCs with high ALDH activity
when cultured under muscle diﬀerentiation conditions with
or without either IGF-2 siRNA or IGF-2 siRNA and extra-
cellular IGFBP-6 at (A) day 1, (B) day 3, (C) day 7, and
(D) day 14. DEAB-treated controls were used to establish
the ALDH gate. Supplementary Figure 5: PMSCs treated
with IGF-1 showed decreased IGF-2 levels secreted into
the media compared to muscle diﬀerentiation. Data is pre-
sented as the mean± SEM of 3 independent experiments.
Two-way ANOVA with Bonferroni’s multiple comparison
test; ∗P < 0 05 and ∗∗∗P < 0 001. (Supplementary Materials)
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